|
Market Cap (3-Jul) $146,035,872 (477th) |
Close (30-Jun) $0.99 |
Volume (30-Jun) 1,077,429 |
Shortsold (19-Jun) 1,473,254 (0.38%) (338th) |
|
52w High $0.66 |
52w Low $0.165 |
P/E - |
EPS -0.05 |
PAR released this announcement to the ASX on 17 December 2020, 16:14. The announcement is not marked as price sensitive, and is 16 page(s) in length and 431.89kb in size.
You can view all announcements from PAR and see how they appear on a price chart on the announcements page.
At the date of this announcement, PAR was 4.074% short sold according to ASIC data. It was ranked the 39th most shorted stock on the ASX. It remains ranked 338th as of the latest reported data (19 June 2025).
| Other Recent Announcements from PAR | |
|---|---|
| Notification of cessation of securities - PAR | 29 June 2023, 16:43 |
| Primary and Secondary endpoints met in MPS I Trial | 6 June 2023, 12:28 |
| iPPS shows 3-year equivalent durability in OA Canine Study | 1 June 2023, 8:21 |
| Cleansing Notice and Appendix 2A | 17 December 2020, 16:14 |
| Initial Director's Interest Notice | 15 December 2020, 18:23 |
| Paradigm Provides Phase 3 Clinical Trial Update | 14 December 2020, 8:23 |
| Paradigm welcomes Amos Meltzer as Non-Executive Director | 9 December 2020, 8:20 |
You must be logged in to post a reply.
Paradigm Biopharmaceuticals 